PERSON: Leonard Schleifer
Employer
Regeneron Pharmaceuticals
Position
CEO & President
Biography
Leonard S. Schleifer (born 1953) is an American businessman and is the co-founder and chief executive of the biotechnology company Regeneron Pharmaceuticals.
As CEO of Regeneron, Schleifer oversaw the “approval and growth of high-priced drugs.” In 2011, Regeneron’s first successful drug was Eylea for age-related macular degeneration.[4] Eylea prevented leaky blood vessels in the eye from causing blindness. He licensed the drug to Aventis which was then bought by Sanofi which had no interest in the eye drug. Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 making Schleifer a billionaire. In 2014 Eylea grossed $1.735 billion.
As CEO Schleifer received a total compensation of $41,965,424 in 2014. According to the “annual collaborative report” from Equilar and The New York Times, Schleifer ranked 15th in the May 2015 list of “200 highest-paid CEOs of large publicly traded companies.” He ranked first in the list of biopharmaceutical executives with the highest total compensation.
The subject is currently working on a multi-center, double-blind, Phase 2/3 trial with the partnership Sanofi, to evaluate the antibody agent, Kevzara(TM) for hospitalized patients starting in March 2020, as well as, working on the development of a novel, multi-antibody cocktail to be used as both a prevention of SARS-CoV-2 and treatment for infected patients. Regeneron’s apparent privileged access of its experimental Covid-19 therapeutic to Donald Trump and members of the Trump Administration drew criticism over ethical concerns.
>> Wikipedia
As CEO of Regeneron, Schleifer oversaw the “approval and growth of high-priced drugs.” In 2011, Regeneron’s first successful drug was Eylea for age-related macular degeneration.[4] Eylea prevented leaky blood vessels in the eye from causing blindness. He licensed the drug to Aventis which was then bought by Sanofi which had no interest in the eye drug. Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 making Schleifer a billionaire. In 2014 Eylea grossed $1.735 billion.
As CEO Schleifer received a total compensation of $41,965,424 in 2014. According to the “annual collaborative report” from Equilar and The New York Times, Schleifer ranked 15th in the May 2015 list of “200 highest-paid CEOs of large publicly traded companies.” He ranked first in the list of biopharmaceutical executives with the highest total compensation.
The subject is currently working on a multi-center, double-blind, Phase 2/3 trial with the partnership Sanofi, to evaluate the antibody agent, Kevzara(TM) for hospitalized patients starting in March 2020, as well as, working on the development of a novel, multi-antibody cocktail to be used as both a prevention of SARS-CoV-2 and treatment for infected patients. Regeneron’s apparent privileged access of its experimental Covid-19 therapeutic to Donald Trump and members of the Trump Administration drew criticism over ethical concerns.
>> Wikipedia
ClipsBank
Full
Compact
NewsBase
Full
Compact
RadioBank
Full
Compact
PodBank
Full
Compact
TranscriptBank
Full
Compact
No data found
